{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:46:20Z","timestamp":1793130380147,"version":"4.5.0"},"reference-count":176,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41380-026-03602-7","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:13:11Z","timestamp":1775664791000},"page":"4799-4810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4553-376X","authenticated-orcid":false,"given":"Johannes G.","family":"Ramaekers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7634-3809","authenticated-orcid":false,"given":"Kim P. C.","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-6164","authenticated-orcid":false,"given":"Franz X.","family":"Vollenweider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"3602_CR1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00115-005-2001-y","volume":"77","author":"U Benzenhofer","year":"2006","unstructured":"Benzenhofer U, Passie T. [The early history of \u201cEcstasy\u201d]. Nervenarzt. 2006;77:95\u201396.","journal-title":"Nervenarzt"},{"key":"3602_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/dta.2292","volume":"10","author":"T Passie","year":"2018","unstructured":"Passie T, Benzenhofer U. MDA, MDMA, and other \u201cmescaline-like\u201d substances in the US military\u2019s search for a truth drug (1940s to 1960s). Drug Test Anal. 2018;10:72\u201380.","journal-title":"Drug Test Anal"},{"key":"3602_CR3","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1111\/j.1360-0443.2010.02948.x","volume":"105","author":"U Benzenhofer","year":"2010","unstructured":"Benzenhofer U, Passie T. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction. 2010;105:1355\u201361.","journal-title":"Addiction"},{"key":"3602_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/02791072.2015.1128580","volume":"48","author":"T Passie","year":"2016","unstructured":"Passie T, Benzenhofer U. The History of MDMA as an underground drug in the United States, 1960-1979. J Psychoactive Drugs. 2016;48:67\u201375.","journal-title":"J Psychoactive Drugs"},{"key":"3602_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/02791072.2001.10400568","volume":"33","author":"AR Pentney","year":"2001","unstructured":"Pentney AR. An exploration of the history and controversies surrounding MDMA and MDA. J Psychoactive Drugs. 2001;33:213\u201321.","journal-title":"J Psychoactive Drugs"},{"key":"3602_CR6","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1523\/JNEUROSCI.19-12-05096.1999","volume":"19","author":"G Hatzidimitriou","year":"1999","unstructured":"Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+\/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci. 1999;19:5096\u2013107.","journal-title":"J Neurosci"},{"key":"3602_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1017\/S1461145712000582","volume":"16","author":"M Mueller","year":"2013","unstructured":"Mueller M, Yuan J, McCann UD, Hatzidimitriou G, Ricaurte GA. Single oral doses of (+\/-) 3,4-methylenedioxymethamphetamine (\u2018Ecstasy\u2019) produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations. Int J Neuropsychopharmacol. 2013;16:791\u2013801.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3602_CR8","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0022-3565(25)38362-X","volume":"266","author":"GA Ricaurte","year":"1993","unstructured":"Ricaurte GA, Markowska AL, Wenk GL, Hatzidimitriou G, Wlos J, Olton DS. 3,4-Methylenedioxymethamphetamine, serotonin and memory. J Pharmacol Exp Ther. 1993;266:1097\u2013105.","journal-title":"J Pharmacol Exp Ther"},{"key":"3602_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1124\/pr.55.3.3","volume":"55","author":"AR Green","year":"2003","unstructured":"Green AR, Mechan AO, Elliott JM, O\u2019Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d). Pharmacol Rev. 2003;55:463\u2013508.","journal-title":"Pharmacol Rev"},{"key":"3602_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2019.146556","volume":"1727","author":"MA Aguilar","year":"2020","unstructured":"Aguilar MA, Garcia-Pardo MP, Parrott AC. Of mice and men on MDMA: A translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine (\u2018Ecstasy\u2019). Brain Res. 2020;1727:146556.","journal-title":"Brain Res"},{"key":"3602_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1159\/000080961","volume":"50","author":"AC Parrott","year":"2004","unstructured":"Parrott AC. MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology. 2004;50:329\u201335.","journal-title":"Neuropsychobiology"},{"key":"3602_CR12","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1177\/0269881117711922","volume":"31","author":"AC Parrott","year":"2017","unstructured":"Parrott AC, Downey LA, Roberts CA, Montgomery C, Bruno R, Fox HC. Recreational 3,4-methylenedioxymethamphetamine or \u2018ecstasy\u2019: Current perspective and future research prospects. J Psychopharmacol. 2017;31:959\u201366.","journal-title":"J Psychopharmacol"},{"key":"3602_CR13","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1007\/s00213-016-4396-5","volume":"233","author":"Y Vegting","year":"2016","unstructured":"Vegting Y, Reneman L, Booij J. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies. Psychopharmacology (Berl). 2016;233:3473\u2013501.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/0269881106059939","volume":"20","author":"E Gouzoulis-Mayfrank","year":"2006","unstructured":"Gouzoulis-Mayfrank E, Daumann J. The confounding problem of polydrug use in recreational ecstasy\/MDMA users: a brief overview. J Psychopharmacol. 2006;20:188\u201393.","journal-title":"J Psychopharmacol"},{"key":"3602_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1360-0443.2006.01314.x","volume":"101","author":"E Gouzoulis-Mayfrank","year":"2006","unstructured":"Gouzoulis-Mayfrank E, Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction. 2006;101:348\u201361.","journal-title":"Addiction"},{"key":"3602_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drugpo.2018.11.002","volume":"64","author":"T Amoroso","year":"2019","unstructured":"Amoroso T. The spurious relationship between ecstasy use and neurocognitive deficits: A Bradford Hill review. Int J Drug Policy. 2019;64:47\u201353.","journal-title":"Int J Drug Policy"},{"key":"3602_CR17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.neubiorev.2017.07.015","volume":"84","author":"CA Roberts","year":"2018","unstructured":"Roberts CA, Quednow BB, Montgomery C, Parrott AC. MDMA and brain activity during neurocognitive performance: An overview of neuroimaging studies with abstinent \u2018Ecstasy\u2019 users. Neurosci Biobehav Rev. 2018;84:470\u201382.","journal-title":"Neurosci Biobehav Rev"},{"key":"3602_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/02791072.2002.10399952","volume":"34","author":"R Doblin","year":"2002","unstructured":"Doblin R. A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. J Psychoactive Drugs. 2002;34:185\u201394.","journal-title":"J Psychoactive Drugs"},{"key":"3602_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/02791072.2008.10400637","volume":"40","author":"JC Bouso","year":"2008","unstructured":"Bouso JC, Doblin R, Farre M, Alcazar MA, Gomez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs. 2008;40:225\u201336.","journal-title":"J Psychoactive Drugs"},{"key":"3602_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u201333.","journal-title":"Nat Med"},{"key":"3602_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pnpbp.2018.03.003","volume":"84","author":"AA Feduccia","year":"2018","unstructured":"Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry. 2018;84:221\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3602_CR22","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"Mitchell","year":"2023","unstructured":"Mitchell, Ot\u2019alora GM JM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29:2473\u201380.","journal-title":"Nat Med"},{"key":"3602_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of +\/-3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011;25:439\u201352.","journal-title":"J Psychopharmacol"},{"key":"3602_CR24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/0269881118806297","volume":"32","author":"GM Ot\u2019alora","year":"2018","unstructured":"Ot\u2019alora GM, Grigsby J, Poulter B, Van Derveer JW 3rd, Giron SG, Jerome L, et al. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. J Psychopharmacol. 2018;32:1295\u2013307.","journal-title":"J Psychopharmacol"},{"key":"3602_CR25","doi-asserted-by":"crossref","unstructured":"Reardon S. MDMA therapy for PTSD rejected by FDA panel. Nature. 2024.","DOI":"10.1038\/d41586-024-01622-3"},{"key":"3602_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jamapsychiatry.2025.0442","volume":"82","author":"ST Wilkinson","year":"2025","unstructured":"Wilkinson ST, Sanacora G. Issues in clinical trial design-lessons from the FDA\u2019s rejection of MDMA. JAMA Psychiatry. 2025;82:545\u20136.","journal-title":"JAMA Psychiatry"},{"key":"3602_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/00048674251315642","volume":"59","author":"A Sze Jing Yong","year":"2025","unstructured":"Sze Jing Yong A, Bratuskins S, Sultani MS, Blakeley B, Davey CG, Bell JS. Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder: An overview of systematic reviews and meta-analyses. Aust N Z J Psychiatry. 2025;59:339\u201360.","journal-title":"Aust N Z J Psychiatry"},{"key":"3602_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.7326\/M23-2757","volume":"177","author":"PP Schnurr","year":"2024","unstructured":"Schnurr PP, Hamblen JL, Wolf J, Coller R, Collie C, Fuller MA, et al. The management of posttraumatic stress disorder and acute stress disorder: Synopsis of the 2023 U.S. department of veterans affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2024;177:363\u201374.","journal-title":"Ann Intern Med"},{"key":"3602_CR29","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s00213-024-06671-0","volume":"241","author":"AA Feduccia","year":"2024","unstructured":"Feduccia AA, Jerome L, Mithoefer MC, Holland J. Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. Psychopharmacology (Berl). 2024;241:2403.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR30","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00213-024-06665-y","volume":"241","author":"L Jerome","year":"2024","unstructured":"Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, et al. Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2024;241:2407.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR31","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1007\/s00213-024-06666-x","volume":"241","author":"MC Mithoefer","year":"2024","unstructured":"Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, et al. Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2024;241:2405.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1176\/appi.ajp.20230681","volume":"182","author":"AS Wolfgang","year":"2025","unstructured":"Wolfgang AS, Fonzo GA, Gray JC, Krystal JH, Grzenda A, Widge AS, et al. MDMA and MDMA-Assisted therapy. Am J Psychiatry. 2025;182:79\u2013103.","journal-title":"Am J Psychiatry"},{"key":"3602_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113888","volume":"347","author":"C Montgomery","year":"2022","unstructured":"Montgomery C, Roberts CA. Neurological and cognitive alterations induced by MDMA in humans. Exp Neurol. 2022;347:113888.","journal-title":"Exp Neurol"},{"key":"3602_CR34","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","volume":"89","author":"G Rudnick","year":"1992","unstructured":"Rudnick G, Wall SC. The molecular mechanism of \u201cecstasy\u201d [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA. 1992;89:1817\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3602_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/02791072.2002.10399951","volume":"34","author":"FX Vollenweider","year":"2002","unstructured":"Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M. Acute psychological and neurophysiological effects of MDMA in humans. J Psychoactive Drugs. 2002;34:171\u201384.","journal-title":"J Psychoactive Drugs"},{"key":"3602_CR36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/hup.348","volume":"16","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol. 2001;16:589\u201398.","journal-title":"Hum Psychopharmacol"},{"key":"3602_CR37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0893-133X(99)00148-7","volume":"22","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000;22:513\u201321.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","volume":"189","author":"M Tancer","year":"2007","unstructured":"Tancer M, Johanson CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2007;189:565\u201373.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR39","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.107.129056","volume":"323","author":"M Farre","year":"2007","unstructured":"Farre M, Abanades S, Roset PN, Peiro AM, Torrens M, O\u2019Mathuna B, et al. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther. 2007;323:954\u201362.","journal-title":"J Pharmacol Exp Ther"},{"key":"3602_CR40","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1136\/emj.2009.079905","volume":"27","author":"CM Hysek","year":"2010","unstructured":"Hysek CM, Vollenweider FX, Liechti ME. Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy). Emerg Med J. 2010;27:586\u20139.","journal-title":"Emerg Med J"},{"key":"3602_CR41","doi-asserted-by":"publisher","first-page":"e36476","DOI":"10.1371\/journal.pone.0036476","volume":"7","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Krahenbuhl S, et al. Duloxetine inhibits effects of MDMA (\u201cecstasy\u201d) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One. 2012;7:e36476.","journal-title":"PLoS One"},{"key":"3602_CR42","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1021\/acschemneuro.8b00155","volume":"9","author":"LE Dunlap","year":"2018","unstructured":"Dunlap LE, Andrews AM, Olson DE. Dark classics in chemical neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chem Neurosci. 2018;9:2408\u201327.","journal-title":"ACS Chem Neurosci"},{"key":"3602_CR43","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s00204-024-03765-8","volume":"98","author":"BA Baldo","year":"2024","unstructured":"Baldo BA. The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns. Arch Toxicol. 2024;98:2409\u201327.","journal-title":"Arch Toxicol"},{"key":"3602_CR44","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0893-133X(00)00126-3","volume":"23","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA (\u201cEcstasy\u201d) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology. 2000;23:396\u2013404.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/164_2018_113","volume":"252","author":"LD Simmler","year":"2018","unstructured":"Simmler LD, Liechti ME. Pharmacology of MDMA- and amphetamine-like new psychoactive substances. Handb Exp Pharmacol. 2018;252:143\u201364.","journal-title":"Handb Exp Pharmacol"},{"key":"3602_CR46","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1177\/0269881121998322","volume":"35","author":"E Studerus","year":"2021","unstructured":"Studerus E, Vizeli P, Harder S, Ley L, Liechti ME. Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies. J Psychopharmacol. 2021;35:556\u201365.","journal-title":"J Psychopharmacol"},{"key":"3602_CR47","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/0269881117691569","volume":"31","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol. 2017;31:576\u201388.","journal-title":"J Psychopharmacol"},{"key":"3602_CR48","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.neuroscience.2007.02.032","volume":"146","author":"MR Thompson","year":"2007","unstructured":"Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (\u201cecstasy\u201d). Neuroscience. 2007;146:509\u201314.","journal-title":"Neuroscience"},{"key":"3602_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.psyneuen.2014.04.006","volume":"46","author":"MG Kirkpatrick","year":"2014","unstructured":"Kirkpatrick MG, Francis SM, Lee R, de Wit H, Jacob S. Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans. Psychoneuroendocrinology. 2014;46:23\u201331.","journal-title":"Psychoneuroendocrinology"},{"key":"3602_CR50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-019-1075-9","volume":"569","author":"R Nardou","year":"2019","unstructured":"Nardou R, Lewis EM, Rothhaas R, Xu R, Yang A, Boyden E, et al. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature. 2019;569:116\u201320.","journal-title":"Nature"},{"key":"3602_CR51","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nature03701","volume":"435","author":"M Kosfeld","year":"2005","unstructured":"Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005;435:673\u20136.","journal-title":"Nature"},{"key":"3602_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","volume":"26","author":"R de la Torre","year":"2004","unstructured":"de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004;26:137\u201344.","journal-title":"Ther Drug Monit"},{"key":"3602_CR53","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/FPC.0000000000000231","volume":"26","author":"Y Schmid","year":"2016","unstructured":"Schmid Y, Vizeli P, Hysek CM, Prestin K, Meyer Zu Schwabedissen HE, Liechti ME. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals. Pharmacogenet Genomics. 2016;26:397\u2013401.","journal-title":"Pharmacogenet Genomics"},{"key":"3602_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.npp.1395197","volume":"19","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (\u201cecstasy\u201d) in MDMA-naive healthy volunteers. Neuropsychopharmacology. 1998;19:241\u201351.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR55","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0893-133X(99)00021-4","volume":"21","author":"HJ Gijsman","year":"1999","unstructured":"Gijsman HJ, Verkes RJ, van Gerven JM, Cohen AF. MDMA study. Neuropsychopharmacology. 1999;21:597.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR56","unstructured":"Vollenweider FX, Gucker P, Sch\u00f6nb\u00e4chler R, Kamber E, Vollenweider-Scherpenhuyzen MFI, Schubiger G, et al. Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans. Conference of the German Society for Psychiatry, Psychotherapy and Neuromedicine 2000."},{"key":"3602_CR57","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00213-012-2761-6","volume":"224","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Liechti ME. Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology (Berl). 2012;224:363\u201376.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR58","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41386-023-01609-0","volume":"48","author":"I Straumann","year":"2023","unstructured":"Straumann I, Ley L, Holze F, Becker AM, Klaiber A, Wey K, et al. Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacology. 2023;48:1840\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR59","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1177\/0269881114542454","volume":"28","author":"Y Schmid","year":"2014","unstructured":"Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti ME. Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol. 2014;28:847\u201356.","journal-title":"J Psychopharmacol"},{"key":"3602_CR60","doi-asserted-by":"crossref","unstructured":"Straumann I, Vizeli P, Avedisian I, Erne L, Noorshams D, Vukalovic I, et al. Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants. Neuropsychopharmacology 2026;51:476\u201385.","DOI":"10.1038\/s41386-025-02248-3"},{"key":"3602_CR61","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/s41380-024-02734-y","volume":"30","author":"M Avram","year":"2025","unstructured":"Avram M, Fortea L, Wollner L, Coenen R, Korda A, Rogg H, et al. Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine. Mol Psychiatry. 2025;30:1297\u2013307.","journal-title":"Mol Psychiatry"},{"key":"3602_CR62","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/0269881117699617","volume":"31","author":"KPC Kuypers","year":"2017","unstructured":"Kuypers KPC, Dolder PC, Ramaekers JG, Liechti ME. Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies. J Psychopharmacol. 2017;31:589\u201398.","journal-title":"J Psychopharmacol"},{"key":"3602_CR63","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/0269881115573806","volume":"29","author":"M Kirkpatrick","year":"2015","unstructured":"Kirkpatrick M, Delton AW, Robertson TE, de Wit H. Prosocial effects of MDMA: A measure of generosity. J Psychopharmacol. 2015;29:661\u20138.","journal-title":"J Psychopharmacol"},{"key":"3602_CR64","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/scan\/nst161","volume":"9","author":"CM Hysek","year":"2014","unstructured":"Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014;9:1645\u201352.","journal-title":"Soc Cogn Affect Neurosci"},{"key":"3602_CR65","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.biopsych.2010.08.003","volume":"68","author":"G Bedi","year":"2010","unstructured":"Bedi G, Hyman D, de Wit H. Is ecstasy an \u201cempathogen\u201d? Effects of +\/-3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry. 2010;68:1134\u201340.","journal-title":"Biol Psychiatry"},{"key":"3602_CR66","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/00004714-200008000-00010","volume":"20","author":"J Cami","year":"2000","unstructured":"Cami J, Farr\u00e9 M, Mas M, Roset PN, Poudevida S, Mas A, et al. Human pharmacology of 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d): psychomotor performance and subjective effects. J Clin Psychopharmacol. 2000;20:455\u201366.","journal-title":"J Clin Psychopharmacol"},{"key":"3602_CR67","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1177\/0269881111405361","volume":"25","author":"KP Kuypers","year":"2011","unstructured":"Kuypers KP, Wingen M, Heinecke A, Formisano E, Ramaekers JG. MDMA intoxication and verbal memory performance: a placebo-controlled pharmaco-MRI study. J Psychopharmacol. 2011;25:1053\u201361.","journal-title":"J Psychopharmacol"},{"key":"3602_CR68","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1038\/npp.2016.75","volume":"41","author":"E Papaseit","year":"2016","unstructured":"Papaseit E, Perez-Mana C, Mateus JA, Pujadas M, Fonseca F, Torrens M, et al. Human pharmacology of mephedrone in comparison with MDMA. Neuropsychopharmacology. 2016;41:2704\u201313.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR69","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/JCP.0b013e31817ef470","volume":"28","author":"EA Kolbrich","year":"2008","unstructured":"Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol. 2008;28:432\u201340.","journal-title":"J Clin Psychopharmacol"},{"key":"3602_CR70","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00213-009-1635-z","volume":"207","author":"G Bedi","year":"2009","unstructured":"Bedi G, Phan KL, Angstadt M, de Wit H. Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl). 2009;207:73\u201383.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR71","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00213-014-3752-6","volume":"232","author":"MG Kirkpatrick","year":"2015","unstructured":"Kirkpatrick MG, de Wit H. MDMA: a social drug in a social context. Psychopharmacology (Berl). 2015;232:1155\u201363.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR72","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0269881110376687","volume":"25","author":"GJ Dumont","year":"2011","unstructured":"Dumont GJ, van Hasselt JG, de Kam M, van Gerven JM, Touw DJ, Buitelaar JK, et al. Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers. J Psychopharmacol. 2011;25:478\u201389.","journal-title":"J Psychopharmacol"},{"key":"3602_CR73","doi-asserted-by":"publisher","first-page":"e0199384","DOI":"10.1371\/journal.pone.0199384","volume":"13","author":"P Vizeli","year":"2018","unstructured":"Vizeli P, Liechti ME. Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects. PLoS One. 2018;13:e0199384.","journal-title":"PLoS One"},{"key":"3602_CR74","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00213-012-2645-9","volume":"222","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Domes G, Liechti ME. MDMA enhances \u201cmind reading\u201d of positive emotions and impairs \u201cmind reading\u201d of negative emotions. Psychopharmacology (Berl). 2012;222:293\u2013302.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR75","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00213-017-4650-5","volume":"235","author":"PC Dolder","year":"2018","unstructured":"Dolder PC, Muller F, Schmid Y, Borgwardt SJ, Liechti ME. Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology (Berl). 2018;235:467\u201379.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR76","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1523\/JNEUROSCI.1276-18.2018","volume":"39","author":"AS Gabay","year":"2019","unstructured":"Gabay AS, Kempton MJ, Gilleen J, Mehta MA. MDMA increases cooperation and recruitment of social brain areas when playing trustworthy players in an iterated Prisoner\u2019s Dilemma. J Neurosci. 2019;39:307\u201320.","journal-title":"J Neurosci"},{"key":"3602_CR77","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0269881120926673","volume":"35","author":"A Borissova","year":"2021","unstructured":"Borissova A, Ferguson B, Wall MB, Morgan CJ, Carhart-Harris RL, Bolstridge M, et al. Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. J Psychopharmacol. 2021;35:547\u201355.","journal-title":"J Psychopharmacol"},{"key":"3602_CR78","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00213-006-0434-z","volume":"187","author":"KP Kuypers","year":"2006","unstructured":"Kuypers KP, Samyn N, Ramaekers JG. MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function. Psychopharmacology (Berl). 2006;187:467\u201375.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR79","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00213-012-2894-7","volume":"225","author":"A Peir\u00f3","year":"2013","unstructured":"Peir\u00f3 A, Farr\u00e9 M, Roset P, Carb\u00f3 M, Pujadas M, Torrens M, et al. Human pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart. Psychopharmacology. 2013;225:883\u201393.","journal-title":"Psychopharmacology"},{"key":"3602_CR80","doi-asserted-by":"publisher","first-page":"e47599","DOI":"10.1371\/journal.pone.0047599","volume":"7","author":"R Pardo-Lozano","year":"2012","unstructured":"Pardo-Lozano R, Farr\u00e9 M, Yubero-Lahoz S, O\u2019Math\u00fana B, Torrens M, Mustata C, et al. Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT). PLOS ONE. 2012;7:e47599.","journal-title":"PLOS ONE"},{"key":"3602_CR81","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00213-017-4699-1","volume":"235","author":"KPC Kuypers","year":"2018","unstructured":"Kuypers KPC, de la Torre R, Farre M, Pizarro N, Xicota L, Ramaekers JG. MDMA-induced indifference to negative sounds is mediated by the 5-HT(2A) receptor. Psychopharmacology (Berl). 2018;235:481\u201390.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR82","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","volume":"86","author":"AK Bershad","year":"2019","unstructured":"Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry. 2019;86:792\u2013800.","journal-title":"Biol Psychiatry"},{"key":"3602_CR83","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ijnp\/pyx112","volume":"21","author":"A Schmidt","year":"2018","unstructured":"Schmidt A, Muller F, Dolder PC, Schmid Y, Zanchi D, Egloff L, et al. Acute effects of methylphenidate, modafinil, and MDMA on negative emotion processing. Int J Neuropsychopharmacol. 2018;21:345\u201354.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3602_CR84","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/02698811231224153","volume":"38","author":"AK Bershad","year":"2024","unstructured":"Bershad AK, Hsu DT, de Wit H. MDMA enhances positive affective responses to social feedback. J Psychopharmacol. 2024;38:297\u2013304.","journal-title":"J Psychopharmacol"},{"key":"3602_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.906639","volume":"13","author":"P Vizeli","year":"2022","unstructured":"Vizeli P, Straumann I, Duthaler U, Varghese N, Eckert A, Paulus MP, et al. Effects of 3,4-Methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects. Front Pharmacol. 2022;13:906639.","journal-title":"Front Pharmacol"},{"key":"3602_CR86","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/0269881115581962","volume":"29","author":"MJ Baggott","year":"2015","unstructured":"Baggott MJ, Kirkpatrick MG, Bedi G, de Wit H. Intimate insight: MDMA changes how people talk about significant others. J Psychopharmacol. 2015;29:669\u201377.","journal-title":"J Psychopharmacol"},{"key":"3602_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26656-2","volume":"8","author":"AS Gabay","year":"2018","unstructured":"Gabay AS, Carhart-Harris RL, Mazibuko N, Kempton MJ, Morrison PD, Nutt DJ, et al. Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. Sci Rep. 2018;8:8236.","journal-title":"Sci Rep"},{"key":"3602_CR88","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/clpt.2011.78","volume":"90","author":"CM Hysek","year":"2011","unstructured":"Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u201cecstasy\u201d) in humans. Clin Pharmacol Ther. 2011;90:246\u201355.","journal-title":"Clin Pharmacol Ther"},{"key":"3602_CR89","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1124\/jpet.114.222356","volume":"353","author":"Y Schmid","year":"2015","unstructured":"Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, et al. Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther. 2015;353:102\u201311.","journal-title":"J Pharmacol Exp Ther"},{"key":"3602_CR90","doi-asserted-by":"publisher","first-page":"e40187","DOI":"10.1371\/journal.pone.0040187","volume":"7","author":"JH van Wel","year":"2012","unstructured":"van Wel JH, Kuypers KP, Theunissen EL, Bosker WM, Bakker K, Ramaekers JG. Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. PLoS One. 2012;7:e40187.","journal-title":"PLoS One"},{"key":"3602_CR91","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s002130000648","volume":"154","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl). 2001;154:161\u20138.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR92","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0924-977X(00)00086-9","volume":"10","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA (\u201cEcstasy\u201d) after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol. 2000;10:289\u201395.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3602_CR93","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuroimage.2019.04.007","volume":"195","author":"O Dipasquale","year":"2019","unstructured":"Dipasquale O, Selvaggi P, Veronese M, Gabay AS, Turkheimer F, Mehta MA. Receptor-Enriched Analysis of functional connectivity by targets (REACT): A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA. Neuroimage. 2019;195:252\u201360.","journal-title":"Neuroimage"},{"key":"3602_CR94","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1177\/0269881108094650","volume":"23","author":"F Hasler","year":"2009","unstructured":"Hasler F, Studerus E, Lindner K, Ludewig S, Vollenweider FX. Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. J Psychopharmacol. 2009;23:923\u201335.","journal-title":"J Psychopharmacol"},{"key":"3602_CR95","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/JCP.0b013e3182979d32","volume":"33","author":"CM Hysek","year":"2013","unstructured":"Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME. alpha(1)-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans. J Clin Psychopharmacol. 2013;33:658\u201366.","journal-title":"J Clin Psychopharmacol"},{"key":"3602_CR96","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1124\/jpet.111.188425","volume":"340","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, et al. Effects of the alpha(2)-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther. 2012;340:286\u201394.","journal-title":"J Pharmacol Exp Ther"},{"key":"3602_CR97","doi-asserted-by":"publisher","first-page":"e100719","DOI":"10.1371\/journal.pone.0100719","volume":"9","author":"KP Kuypers","year":"2014","unstructured":"Kuypers KP, de la Torre R, Farre M, Yubero-Lahoz S, Dziobek I, Van den Bos W, et al. No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLoS One. 2014;9:e100719.","journal-title":"PLoS One"},{"key":"3602_CR98","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.neulet.2016.07.004","volume":"649","author":"B Sessa","year":"2017","unstructured":"Sessa B. MDMA and PTSD treatment: \u201cPTSD: From novel pathophysiology to innovative therapeutics\u201d. Neurosci Lett. 2017;649:176\u201380.","journal-title":"Neurosci Lett"},{"key":"3602_CR99","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41386-020-00803-8","volume":"46","author":"BD Heifets","year":"2021","unstructured":"Heifets BD, Malenka RC. Better living through chemistry: MDMA\u2019s prosocial mechanism as a starting point for improved therapeutics. Neuropsychopharmacology. 2021;46:261.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR100","doi-asserted-by":"publisher","DOI":"10.1080\/20008066.2023.2297536","volume":"15","author":"RJ Zeifman","year":"2024","unstructured":"Zeifman RJ, Kettner H, Ross S, Weiss B, Mithoefer MC, Mithoefer AT, et al. Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder. Eur J Psychotraumatol. 2024;15:2297536.","journal-title":"Eur J Psychotraumatol"},{"key":"3602_CR101","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/cpp.2642","volume":"29","author":"R Howard","year":"2022","unstructured":"Howard R, Berry K, Haddock G. Therapeutic alliance in psychological therapy for posttraumatic stress disorder: A systematic review and meta-analysis. Clin Psychol Psychother. 2022;29:373\u201399.","journal-title":"Clin Psychol Psychother"},{"key":"3602_CR102","doi-asserted-by":"publisher","DOI":"10.1080\/20008066.2025.2485513","volume":"16","author":"G Agin-Liebes","year":"2025","unstructured":"Agin-Liebes G, Zeifman RJ, Mitchell JM. Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder. Eur J Psychotraumatol. 2025;16:2485513.","journal-title":"Eur J Psychotraumatol"},{"key":"3602_CR103","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","volume":"23","author":"E Krediet","year":"2020","unstructured":"Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020;23:385\u2013400.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3602_CR104","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","volume":"80","author":"S McNamee","year":"2023","unstructured":"McNamee S, Devenot N, Buisson M. Studying harms is key to improving psychedelic-assisted therapy-participants call for changes to research landscape. JAMA Psychiatry. 2023;80:411\u20132.","journal-title":"JAMA Psychiatry"},{"key":"3602_CR105","first-page":"821","volume":"92","author":"HV Curran","year":"1997","unstructured":"Curran HV, Travill RA. Mood and cognitive effects of +\/-3,4-methylenedioxymethamphetamine (MDMA, \u2018ecstasy\u2019): week-end \u2018high\u2019 followed by mid-week low. Addiction. 1997;92:821\u201331.","journal-title":"Addiction"},{"key":"3602_CR106","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fpsyt.2019.00138","volume":"10","author":"B Sessa","year":"2019","unstructured":"Sessa B, Higbed L, Nutt D. A review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted psychotherapy. Front Psychiatry. 2019;10:138.","journal-title":"Front Psychiatry"},{"key":"3602_CR107","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00213-001-0995-9","volume":"161","author":"SL Verheyden","year":"2002","unstructured":"Verheyden SL, Hadfield J, Calin T, Curran HV. Sub-acute effects of MDMA (+\/-3,4-methylenedioxymethamphetamine, \u201cecstasy\u201d) on mood: evidence of gender differences. Psychopharmacology (Berl). 2002;161:23\u201331.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR108","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41386-024-01865-8","volume":"49","author":"J Colcott","year":"2024","unstructured":"Colcott J, Guerin AA, Carter O, Meikle S, Bedi G. Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis. Neuropsychopharmacology. 2024;49:1208\u201326.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR109","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1177\/02698811221100713","volume":"36","author":"J Flameling","year":"2022","unstructured":"Flameling J, van der Does F, van Veelen N, Vermetten E. Not too quick on \u201cDebunking the myth of \u2018Blue Mondays\u2019\u201c. J Psychopharmacol. 2022;36:1001\u20134.","journal-title":"J Psychopharmacol"},{"key":"3602_CR110","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00213-006-0601-2","volume":"189","author":"AD Kalechstein","year":"2007","unstructured":"Kalechstein AD, De La Garza R 2nd, Mahoney JJ 3rd, Fantegrossi WE, Newton TF. MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl). 2007;189:531\u20137.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR111","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/archpsyc.64.6.728","volume":"64","author":"T Schilt","year":"2007","unstructured":"Schilt T, de Win MM, Koeter M, Jager G, Korf DJ, van den Brink W, et al. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch Gen Psychiatry. 2007;64:728\u201336.","journal-title":"Arch Gen Psychiatry"},{"key":"3602_CR112","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/archgenpsychiatry.2007.36","volume":"65","author":"TS Krebs","year":"2008","unstructured":"Krebs TS, Johansen PO. No evidence of decrease in cognitive function in users of low-dose Ecstasy. Arch Gen Psychiatry. 2008;65:236.","journal-title":"Arch Gen Psychiatry"},{"key":"3602_CR113","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/0269881105056670","volume":"19","author":"KP Kuypers","year":"2005","unstructured":"Kuypers KP, Ramaekers JG. Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine. J Psychopharmacol. 2005;19:633\u20139.","journal-title":"J Psychopharmacol"},{"key":"3602_CR114","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00213-006-0321-7","volume":"189","author":"KP Kuypers","year":"2007","unstructured":"Kuypers KP, Ramaekers JG. Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected. Psychopharmacology (Berl). 2007;189:557\u201363.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR115","doi-asserted-by":"publisher","first-page":"e0149438","DOI":"10.1371\/journal.pone.0149438","volume":"11","author":"KP Kuypers","year":"2016","unstructured":"Kuypers KP, Theunissen EL, van Wel JH, de Sousa Fernandes Perna EB, Linssen A, Sambeth A, et al. Verbal memory impairment in polydrug ecstasy users: a clinical perspective. PLoS One. 2016;11:e0149438.","journal-title":"PLoS One"},{"key":"3602_CR116","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/npp.2008.219","volume":"34","author":"JG Ramaekers","year":"2009","unstructured":"Ramaekers JG, Kuypers KP, Wingen M, Heinecke A, Formisano E. Involvement of inferior parietal lobules in prospective memory impairment during acute MDMA (ecstasy) intoxication: an event-related fMRI study. Neuropsychopharmacology. 2009;34:1641\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR117","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.euroneuro.2022.01.005","volume":"57","author":"L Kloft","year":"2022","unstructured":"Kloft L, Otgaar H, Blokland A, Toennes SW, Ramaekers JG. Remembering Molly: Immediate and delayed false memory formation after acute MDMA exposure. Eur Neuropsychopharmacol. 2022;57:59\u201368.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3602_CR118","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/npp.2011.80","volume":"36","author":"JH van Wel","year":"2011","unstructured":"van Wel JH, Kuypers KP, Theunissen EL, Bosker WM, Bakker K, Ramaekers JG. Blockade of 5-HT2 receptor selectively prevents MDMA-induced verbal memory impairment. Neuropsychopharmacology. 2011;36:1932\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR119","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1476-5381.2012.02196.x","volume":"168","author":"KP Kuypers","year":"2013","unstructured":"Kuypers KP, de la Torre R, Farre M, Pujadas M, Ramaekers JG. Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory. Br J Pharmacol. 2013;168:607\u201317.","journal-title":"Br J Pharmacol"},{"key":"3602_CR120","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.neuropharm.2014.03.008","volume":"87","author":"EB de Sousa Fernandes Perna","year":"2014","unstructured":"de Sousa Fernandes Perna EB, Theunissen EL, Kuypers KP, Heckman P, de la Torre R, Farre M, et al. Memory and mood during MDMA intoxication, with and without memantine pretreatment. Neuropharmacology. 2014;87:198\u2013205.","journal-title":"Neuropharmacology"},{"key":"3602_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2023.110843","volume":"128","author":"M Sarmanlu","year":"2024","unstructured":"Sarmanlu M, Kuypers KPC, Vizeli P, Kvamme TL. MDMA-assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy. Prog Neuropsychopharmacol Biol Psychiatry. 2024;128:110843.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3602_CR122","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/02698811211069124","volume":"36","author":"JL Maples-Keller","year":"2022","unstructured":"Maples-Keller JL, Norrholm SD, Burton M, Reiff C, Coghlan C, Jovanovic T, et al. A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. J Psychopharmacol. 2022;36:368\u201377.","journal-title":"J Psychopharmacol"},{"key":"3602_CR123","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/npp.2017.171","volume":"43","author":"MK Doss","year":"2018","unstructured":"Doss MK, Weafer J, Gallo DA, de Wit H. MDMA impairs both the encoding and retrieval of emotional recollections. Neuropsychopharmacology. 2018;43:791\u2013800.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR124","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1017\/S1461145713001405","volume":"17","author":"RL Carhart-Harris","year":"2014","unstructured":"Carhart-Harris RL, Wall MB, Erritzoe D, Kaelen M, Ferguson B, De Meer I, et al. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol. 2014;17:527\u201340.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3602_CR125","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/sj.npp.1300894","volume":"31","author":"JG Ramaekers","year":"2006","unstructured":"Ramaekers JG, Kuypers KP. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on behavioral measures of impulsivity: alone and in combination with alcohol. Neuropsychopharmacology. 2006;31:1048\u201355.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR126","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/j.1360-0443.2006.01566.x","volume":"101","author":"JG Ramaekers","year":"2006","unstructured":"Ramaekers JG, Kuypers KP, Samyn N. Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal. Addiction. 2006;101:1614\u201321.","journal-title":"Addiction"},{"key":"3602_CR127","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/0269881103174015","volume":"17","author":"CT Lamers","year":"2003","unstructured":"Lamers CT, Ramaekers JG, Muntjewerff ND, Sikkema KL, Samyn N, Read NL, et al. Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol. 2003;17:379\u201387.","journal-title":"J Psychopharmacol"},{"key":"3602_CR128","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/0269881105053287","volume":"19","author":"FX Vollenweider","year":"2005","unstructured":"Vollenweider FX, Liechti ME, Paulus MP. MDMA affects both error-rate dependent and independent aspects of decision-making in a two-choice prediction task. J Psychopharmacol. 2005;19:366\u201374.","journal-title":"J Psychopharmacol"},{"key":"3602_CR129","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/02791072.1986.10472366","volume":"18","author":"J Downing","year":"1986","unstructured":"Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs. 1986;18:335\u201340.","journal-title":"J Psychoactive Drugs"},{"key":"3602_CR130","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00213-011-2532-9","volume":"220","author":"C Stough","year":"2012","unstructured":"Stough C, King R, Papafotiou K, Swann P, Ogden E, Wesnes K, et al. The acute effects of 3,4-methylenedioxymethamphetamine and d-methamphetamine on human cognitive functioning. Psychopharmacology. 2012;220:799\u2013807.","journal-title":"Psychopharmacology"},{"key":"3602_CR131","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.aap.2011.08.017","volume":"45","author":"C Stough","year":"2012","unstructured":"Stough C, Downey LA, King R, Papafotiou K, Swann P, Ogden E. The acute effects of 3, 4-methylenedioxymethamphetamine and methamphetamine on driving: a simulator study. Accid Anal Prev. 2012;45:493\u20137.","journal-title":"Accid Anal Prev"},{"key":"3602_CR132","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1124\/jpet.300.1.236","volume":"300","author":"C Hernandez-Lopez","year":"2002","unstructured":"Hernandez-Lopez C, Farre M, Roset PN, Menoyo E, Pizarro N, Ortuno J, et al. 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther. 2002;300:236\u201344.","journal-title":"J Pharmacol Exp Ther"},{"key":"3602_CR133","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.euroneuro.2015.05.007","volume":"25","author":"M Farr\u00e9","year":"2015","unstructured":"Farr\u00e9 M, Tomillero A, P\u00e9rez-Ma\u00f1\u00e1 C, Yubero S, Papaseit E, Roset P-N, et al. Human pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart. European neuropsychopharmacology. 2015;25:1637\u201349.","journal-title":"European neuropsychopharmacology"},{"key":"3602_CR134","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.forsciint.2012.02.025","volume":"220","author":"LA Downey","year":"2012","unstructured":"Downey LA, King R, Papafotiou K, Swann P, Ogden E, Stough C. Examining the effect of dl-3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on the Standardized Field Sobriety Tests. Forensic Sci Int. 2012;220:e33\u20136.","journal-title":"Forensic Sci Int"},{"key":"3602_CR135","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s002130050960","volume":"143","author":"FX Vollenweider","year":"1999","unstructured":"Vollenweider FX, Remensberger S, Hell D, Geyer MA. Opposite effects of 3, 4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology. 1999;143:365\u201372.","journal-title":"Psychopharmacology"},{"key":"3602_CR136","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1177\/0269881117711712","volume":"31","author":"MT Wagner","year":"2017","unstructured":"Wagner MT, Mithoefer MC, Mithoefer AT, MacAulay RK, Jerome L, Yazar-Klosinski B, et al. Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol. 2017;31:967\u201374.","journal-title":"J Psychopharmacol"},{"key":"3602_CR137","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1016\/S0024-3205(01)01373-X","volume":"69","author":"R Pacifici","year":"2001","unstructured":"Pacifici R, Zuccaro P, Farr\u00e9 M, Pichini S, Di Carlo S, Roset PN, et al. Effects of repeated doses of MDMA (\u201cecstasy\u201d) on cell-mediated immune response in humans. Life Sciences. 2001;69:2931\u201341.","journal-title":"Life Sciences"},{"key":"3602_CR138","doi-asserted-by":"publisher","first-page":"Pl309","DOI":"10.1016\/S0024-3205(99)00555-X","volume":"65","author":"R Pacifici","year":"1999","unstructured":"Pacifici R, Zuccaro P, Farr\u00e9 M, Pichini S, Di Carlo S, Roset PN, et al. Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sciences. 1999;65:Pl309\u2013316.","journal-title":"Life Sciences"},{"key":"3602_CR139","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1749-6632.2002.tb04183.x","volume":"965","author":"R Pacifici","year":"2002","unstructured":"Pacifici R, Zuccaro P, Farr\u00e9 M, Pichini S, Di Carlo S, Roset PN, et al. Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Annals of the New York Academy of Sciences. 2002;965:421\u201333.","journal-title":"Annals of the New York Academy of Sciences"},{"key":"3602_CR140","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0022-3565(24)29682-8","volume":"296","author":"R Pacifici","year":"2001","unstructured":"Pacifici R, Zuccaro P, Hernandez L\u00f3pez C, Pichini S, Di Carlo S, Farr\u00e9 M, et al. Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther. 2001;296:207\u201315.","journal-title":"J Pharmacol Exp Ther"},{"key":"3602_CR141","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1124\/jpet.103.061374","volume":"309","author":"R Pacifici","year":"2004","unstructured":"Pacifici R, Pichini S, Zuccaro P, Farr\u00e9 M, Segura M, Ortu\u00f1o J, et al. Paroxetine inhibits acute effects of 3,4-Methylenedioxymethamphetamine on the immune system in humans. The Journal of Pharmacology and Experimental Therapeutics. 2004;309:285\u201392.","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"3602_CR142","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00213-011-2537-4","volume":"222","author":"JL Veldstra","year":"2012","unstructured":"Veldstra JL, Brookhuis KA, de Waard D, Molmans BH, Verstraete AG, Skopp G, et al. Effects of alcohol (BAC 0.5 per thousand) and ecstasy (MDMA 100 mg) on simulated driving performance and traffic safety. Psychopharmacology (Berl). 2012;222:377\u201390.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR143","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00213-010-2031-4","volume":"213","author":"MM Lansbergen","year":"2011","unstructured":"Lansbergen MM, Dumont GJ, van Gerven JM, Buitelaar JK, Verkes RJ. Acute effects of MDMA (3,4-methylenedioxymethamphetamine) on EEG oscillations: alone and in combination with ethanol or THC (delta-9-tetrahydrocannabinol). Psychopharmacology (Berl). 2011;213:745\u201356.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR144","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00213-007-1056-9","volume":"197","author":"GJ Dumont","year":"2008","unstructured":"Dumont GJ, Wezenberg E, Valkenberg MM, de Jong CA, Buitelaar JK, van Gerven JM, et al. Acute neuropsychological effects of MDMA and ethanol (co-)administration in healthy volunteers. Psychopharmacology (Berl). 2008;197:465\u201374.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR145","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881108099214","volume":"24","author":"GJ Dumont","year":"2010","unstructured":"Dumont GJ, Schoemaker RC, Touw DJ, Sweep FC, Buitelaar JK, van Gerven JM, et al. Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. J Psychopharmacol. 2010;24:155\u201364.","journal-title":"J Psychopharmacol"},{"key":"3602_CR146","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1017\/S1461145713001132","volume":"17","author":"CM Hysek","year":"2014","unstructured":"Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, et al. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharmacol. 2014;17:371\u201381.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3602_CR147","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00213-006-0679-6","volume":"192","author":"KP Kuypers","year":"2007","unstructured":"Kuypers KP, Wingen M, Samyn N, Limbert N, Ramaekers JG. Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night. Psychopharmacology (Berl). 2007;192:111\u20139.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR148","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00213-009-1767-1","volume":"209","author":"WM Bosker","year":"2010","unstructured":"Bosker WM, Kuypers KP, Conen S, Ramaekers JG. Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss. Psychopharmacology (Berl). 2010;209:69\u201376.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR149","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1177\/02698811080220081401","volume":"22","author":"KP Kuypers","year":"2008","unstructured":"Kuypers KP, Wingen M, Ramaekers JG. Memory and mood during the night and in the morning after repeated evening doses of MDMA. J Psychopharmacol. 2008;22:895\u2013903.","journal-title":"J Psychopharmacol"},{"key":"3602_CR150","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.euroneuro.2017.01.008","volume":"27","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Schmid Y, Prestin K, Meyer zu Schwabedissen HE, Liechti ME. Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. European Neuropsychopharmacology. 2017;27:232\u20138.","journal-title":"European Neuropsychopharmacology"},{"key":"3602_CR151","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1021\/acschemneuro.8b00590","volume":"10","author":"P Vizeli","year":"2019","unstructured":"Vizeli P, Meyer Zu Schwabedissen HE, Liechti ME. Role of serotonin transporter and receptor gene variations in the acute effects of MDMA in healthy subjects. ACS Chem Neurosci. 2019;10:3120\u201331.","journal-title":"ACS Chem Neurosci"},{"key":"3602_CR152","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/11584550-000000000-00000","volume":"50","author":"S Yubero-Lahoz","year":"2011","unstructured":"Yubero-Lahoz S, Pardo R, Farr\u00e9 M, O\u2019Mahony B, Torrens M, Mustata C, et al. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clinical pharmacokinetics. 2011;50:319\u201329.","journal-title":"Clinical pharmacokinetics"},{"key":"3602_CR153","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/sj.npp.1300442","volume":"29","author":"WE Fantegrossi","year":"2004","unstructured":"Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, et al. Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology. 2004;29:1270\u201381.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR154","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1007\/s00213-018-5026-1","volume":"235","author":"Q Highgate","year":"2018","unstructured":"Highgate Q, Schenk S. Comparison of the effects of abstinence on MDMA and cocaine self-administration in rats. Psychopharmacology (Berl). 2018;235:3233\u201341.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR155","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","volume":"237","author":"L Jerome","year":"2020","unstructured":"Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020;237:2485\u201397.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105188","volume":"150","author":"MK Doss","year":"2023","unstructured":"Doss MK, de Wit H, Gallo DA. The acute effects of psychoactive drugs on emotional episodic memory encoding, consolidation, and retrieval: A comprehensive review. Neurosci Biobehav Rev. 2023;150:105188.","journal-title":"Neurosci Biobehav Rev"},{"key":"3602_CR157","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/cpt.3459","volume":"117","author":"A Halman","year":"2025","unstructured":"Halman A, Conyers R, Moore C, Khatri D, Sarris J, Perkins D. Harnessing pharmacogenomics in clinical research on psychedelic-assisted therapy. Clin Pharmacol Ther. 2025;117:106\u201315.","journal-title":"Clin Pharmacol Ther"},{"key":"3602_CR158","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","volume":"236","author":"MC Mithoefer","year":"2019","unstructured":"Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019;236:2735\u201345.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR159","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","volume":"239","author":"JS Aday","year":"2022","unstructured":"Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology (Berl). 2022;239:1989\u20132010.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR160","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1021\/acschemneuro.3c00692","volume":"14","author":"LJ Flameling","year":"2023","unstructured":"Flameling LJ, Aday JS, van Elk M. Expectancy effects cannot be neglected in MDMA-Assisted therapy research. ACS Chem Neurosci. 2023;14:4062\u20133.","journal-title":"ACS Chem Neurosci"},{"key":"3602_CR161","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14:1133\u201352.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3602_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34938-7","volume":"13","author":"B Szigeti","year":"2023","unstructured":"Szigeti B, Nutt D, Carhart-Harris R, Erritzoe D. The difference between \u2018placebo group\u2019 and \u2018placebo control\u2019: a case study in psychedelic microdosing. Sci Rep. 2023;13:12107.","journal-title":"Sci Rep"},{"key":"3602_CR163","doi-asserted-by":"publisher","first-page":"14636","DOI":"10.3390\/ijms232314636","volume":"23","author":"L Poyatos","year":"2022","unstructured":"Poyatos L, Lo Faro AF, Berardinelli D, Sprega G, Malaca S, Pichini S, et al. Methylone and MDMA pharmacokinetics following controlled administration in humans. Int J Mol Sci. 2022;23:14636.","journal-title":"Int J Mol Sci"},{"key":"3602_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1122861","volume":"14","author":"L Poyatos","year":"2023","unstructured":"Poyatos L, Perez-Mana C, Hladun O, Nunez-Montero M, de la Rosa G, Martin S, et al. Pharmacological effects of methylone and MDMA in humans. Front Pharmacol. 2023;14:1122861.","journal-title":"Front Pharmacol"},{"key":"3602_CR165","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3389\/fphar.2019.01588","volume":"10","author":"E Papaseit","year":"2019","unstructured":"Papaseit E, Perez-Mana C, de Sousa Fernandes Perna EB, Olesti E, Mateus J, Kuypers KP, et al. Mephedrone and alcohol interactions in humans. Front Pharmacol. 2019;10:1588.","journal-title":"Front Pharmacol"},{"key":"3602_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1626692","volume":"16","author":"G De la Rosa","year":"2025","unstructured":"De la Rosa G, Papaseit E, Hladun O, Poyatos L, Caicedo DA, Argote MC, et al. Acute pharmacological effects of alpha-PVP in humans: a naturalistic observational study. Front Pharmacol. 2025;16:1626692.","journal-title":"Front Pharmacol"},{"key":"3602_CR167","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00213-025-06798-8","volume":"242","author":"JG Ramaekers","year":"2025","unstructured":"Ramaekers JG, Reckweg JT, Mason NL, Kuypers KP, Toennes SW, Theunissen EL. Low to moderate doses of 3-methylmethcathinone (3-MMC) produce analgesic effects in healthy volunteers: a proof of principle study with a designer drug. Psychopharmacology (Berl). 2025;242:2293\u2013301.","journal-title":"Psychopharmacology (Berl)"},{"key":"3602_CR168","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41386-024-02042-7","volume":"50","author":"JG Ramaekers","year":"2025","unstructured":"Ramaekers JG, Reckweg JT, Mason NL, Kuypers KPC, Toennes SW, Theunissen EL. Safety and cognitive pharmacodynamics following dose escalations with 3-methylmethcathinone (3-MMC): a first in human, designer drug study. Neuropsychopharmacology. 2025;50:1084\u201392.","journal-title":"Neuropsychopharmacology"},{"key":"3602_CR169","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1177\/0269881116662635","volume":"30","author":"EB de Sousa Fernandes Perna","year":"2016","unstructured":"de Sousa Fernandes Perna EB, Papaseit E, Perez-Mana C, Mateus J, Theunissen EL, Kuypers K, et al. Neurocognitive performance following acute mephedrone administration, with and without alcohol. J Psychopharmacol. 2016;30:1305\u201312.","journal-title":"J Psychopharmacol"},{"key":"3602_CR170","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/164_2018_178","volume":"252","author":"MH Baumann","year":"2018","unstructured":"Baumann MH, Walters HM, Niello M, Sitte HH. Neuropharmacology of synthetic cathinones. Handb Exp Pharmacol. 2018;252:113\u201342.","journal-title":"Handb Exp Pharmacol"},{"key":"3602_CR171","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00204-020-02693-7","volume":"94","author":"D Luethi","year":"2020","unstructured":"Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol. 2020;94:1085\u2013133.","journal-title":"Arch Toxicol"},{"key":"3602_CR172","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fphar.2020.00233","volume":"11","author":"E Papaseit","year":"2020","unstructured":"Papaseit E, Olesti E, Perez-Mana C, Torrens M, Grifell M, Ventura M, et al. Acute effects of 2C-E in humans: an observational study. Front Pharmacol. 2020;11:233.","journal-title":"Front Pharmacol"},{"key":"3602_CR173","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/cpt.2958","volume":"114","author":"P Mallaroni","year":"2023","unstructured":"Mallaroni P, Mason NL, Reckweg JT, Paci R, Ritscher S, Toennes SW, et al. Assessment of the acute effects of 2C-B vs. psilocybin on subjective experience, mood, and cognition. Clin Pharmacol Ther. 2023;114:423\u201333.","journal-title":"Clin Pharmacol Ther"},{"key":"3602_CR174","first-page":"1048","volume":"9","author":"MK Doss","year":"2024","unstructured":"Doss MK, Mallaroni P, Mason NL, Ramaekers JG. Psilocybin and 2C-B at encoding distort episodic familiarity. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9:1048\u201357.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"3602_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1353131","volume":"18","author":"J Warner-Schmidt","year":"2024","unstructured":"Warner-Schmidt J, Stogniew M, Mandell B, Rowland RS, Schmidt EF, Kelmendi B. Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA. Front Neurosci. 2024;18:1353131.","journal-title":"Front Neurosci"},{"key":"3602_CR176","doi-asserted-by":"publisher","unstructured":"Jones A, Warner-Schmidt J, Kwak H, Stogniew M, Mandell B, Ching THW, et al. Efficacy and safety of the neuroplastogen TSND-201 for the treatment of PTSD: A randomized clinical trial. JAMA Psychiatry 2026. Published online: https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.4625.","DOI":"10.1001\/jamapsychiatry.2025.4625"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03602-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03602-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03602-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:03:11Z","timestamp":1783926191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03602-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":176,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3602"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03602-7","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}